مقايسه تأثير نیکوتینیک اسید و سولامر بر فسفر بالای سرم در بیماران همودیالیزی: یک مطالعه کارآزمایی بالینی دوسویه کور

Amerian M, Sohrabi MB, Zolfaghari P,Yarmohammadi M, Nezakati E, Yahyaei E, et al. Effects of niasine on serum phosphorus, PTH and lipid profile in the hemodialysis patients in Shahroud city. Medical Sciences Journal of Islamic Azad University, Tehran Medical Branch 2015;24:221-6.[Persian].

Berns JS. Niacin and related compounds for treating hyperphatemia in dialysis patients. Semin Dial 2013;21:203-5.

Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspect of parathyroid hyperplasia in chronic kidney disease. Kidney Intt 2012; 20:53-7.

Dusso AS, Sato T, Arcidiacono MV, Álvarez-Hernández D, Yang J, Gonzáles-Suárez I,et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl 2006;70:S8-11.

Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodialysis Int 2013;10:225-34.

Foley RN, Murray AM, Li S. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united states medicare population, 1998 to 1999. J Am Soc Nephrol 2012; 16:489-95.

Ossareh S. Clinical and economic aspects of sevelamer therapy in end- stage renal disease patients. Int J Nephrol Renovasc Dis 2014; 7:161-8.

Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV, Degaspari S, et al. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 2014;27:25-35.

Oka Y, Miyazaki M, Matsuda H, Takatsu S, Katsube R, Mori T, et al. Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan. Ther Apher Dial 2014;18:37-43.

Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevent the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenina-induced renal failure. Nephrol Dial Transplant 2012;20:1378-84.

Debiec H, Lorenc R. Identification of Na, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 2013; 25:185-191.

Field J, Zhang Li, Brun KA, Brooks DP, Edwards RM. Cloning and functional characterization of a sodium dependent phosphate transporter expressed in human lung and small intestine. Bioch Bioph Res Comm 2012;58:578-82.

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2012;12:2131-8.

Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2013;15:770-9.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2013;15:2208-18.

Young EW, Akiba T, Albert J. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2014;44:34-8.

Kestenbaum B, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2012;16:520-8.

Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int 2013;29:190-4.

Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2011; 18:2809-13.

Yusuf AA, Weinhandl ED, St Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. Am J Kidney Dis 2014;64:95-103.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant 2014;29:152-60.

Hatakeyama S, Murasawa H, Narita T, Oikawa M, Fujita N, Iwamura H, et al. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013;14:222.

Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 2012;14:610-4.

Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. Am J Physiol 2011;27:756-62.

Bover J, Herbener O, Ballarín J, Andrés E, Barceló P. Nuevas estrategias para el hiperparatiroidismo secundario en diálisis (1): nuevos conceptos, nuevos tratamientos. Nefrología 2014;25:100-8.

Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada V, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2012;15:1099-1104.

Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M. Niceritrol decreases serum phosphate levels in hemodialysis patients. Nihon Jinzo Gakkai Shi 1998;40:1-7.

Shahapuni I, Rahmouni K, Harbouche L, El Esper N, Fournier A. Great cost effectiveness of nicotinamide compared with that sevelamer for controlling hyperphosphatemia in dialysis patients 2007. World Congress of Nephrology 2013;20:131-7.